Merck Pledges Billions for U.S. Plants to Dodge 100% Drug Tariff
Merck has pledged billions to expand U.S. manufacturing capacity and stockpile inventory to avoid a potential 100% tariff on imported patented medicines. The administration’s plan delays enforcement for firms investing domestically, prompting accelerated site development and pricing commitments to secure multi-year exemptions.
1. Tariff Proposal and Grace Period
The administration is considering a 100% duty on imported branded and patented medicines, targeting companies that do not invest in U.S. manufacturing. Enforcement of the tariff is suspended for firms committing to domestic projects, offering a multi-year grace period to secure exemptions.
2. Merck's U.S. Expansion Strategy
Merck has committed billions toward building and upgrading U.S. manufacturing facilities and increasing inventory stockpiles to qualify for tariff relief. The company is accelerating project timelines and exploring pricing and platform commitments to solidify its exemption status and strengthen supply chain resilience.